
|Videos|August 4, 2017
Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC
Author(s)Brian I. Rini, MD
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).
Advertisement
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).
There was a trial of 52 previously untreated patients with RCC who received axitinib and prembrolizumab. The response rate with this combination was 71%, whereas single-agent axitinib typically sees response rates in the 30% to 40% range, making these results the best that has been seen in RCC, states Rini.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































